Exploring the Role of Calcium Sensing Receptor in Septic Shock
Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock
This study is trying to see how a specific receptor in the immune cells of patients with septic shock affects their body's response and calcium levels, which could lead to new treatment options.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 66 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Amiens) |
| Trial ID | NCT06853340 on ClinicalTrials.gov |
What this trial studies
This study investigates the expression of the Calcium Sensing Receptor (CaSR) in monocytes of patients experiencing septic shock. It aims to understand how CaSR activation affects immune responses and calcium balance during this critical condition. By analyzing blood samples from intensive care patients within the first 24 hours of septic shock, the study seeks to identify potential therapeutic implications related to CaSR modulation. This research could provide insights into the phosphocalcic disturbances commonly observed in septic shock.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who are in septic shock and have elevated lactate levels.
Not a fit: Patients with hemorrhagic shock, certain genetic disorders, or those on immunosuppressive treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies targeting CaSR to improve outcomes in septic shock patients.
How similar studies have performed: While this approach is novel in the context of septic shock, similar studies have shown promising results in other conditions related to CaSR expression.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female patients over the age of 18, * patients who have not participated in a study evaluating an investigational drug in the 30 days preceding the samples, * intensive care patients in a state of septic shock within the first 24 hours of the introduction of pressor amines, * French resident year-round, * lactate \> 2mmol/L, * patients with social security coverage. Exclusion Criteria: * Patients in hemorrhagic shock, * history of parathyroidectomy, patient with hypersecretion of PTHrp, * sarcoidosis, * genetic disturbance of CaSR including familial hypocalciuric hypercalcaemia, * current immunosuppressant treatment (anticalcineurin, mTOR inhibitor, methotrexate, high-dose corticosteroids excluding hydrocortisone and fludrocortisone), * chronic myelomonocytic leukemia, * patients with febrile neutropenia, * patients with acquired or constitutional immune system, * pregnant or breastfeeding patient, * patients under curators, guardianship or safeguard of justice.
Where this trial is running
Amiens
- CHRU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Quintana SOULIER
- Email: Soulier-Zaninka.Quintana@chu-amiens.fr
- Phone: 33+322057870
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.